However, our and other cross-sectional studies did not find differences in CSF GFAP in CU A+ compared to CU A− (Benedet et al, 2021; Pereira et al, 2021), underlining the strength of our approach to detect disease-driving pathways not detected by single biomarker analysis in early AD. Here, GFAP is linked to Alzheimer disease.